

Table S1 – Development of donor-specific and nondonor-specific antibodies in recipients of IA group.

Subject	N of donors	DSA	Antigen specificity (MFI)					Nondonor-specific antibodies
			Donor 1	Donor 2	Donor 3	Donor 4	Donor 5	
#1	2	+	A1 (11 248), A24 (11 843), B35 (3060), B57 (17 779), DR 7 (>3000)	A1 (11 248), B38 (11 785) B57 (17 779), DR7 (>3000)	NA	NA	NA	A23, A25, A32, A36, A80, B13, B27, B35, B37, B44, B45, B47, B49, B51, B52, B53, B58, B59, B63, B76, B77, B82
#2	2	-	Not detected	Not detected	NA	NA	NA	A1, A25, A26, A66, B38, B39, B76, B8, DQ7 (8432), DQ8 (5876), DQ9 (7151), DqA1 (12 188)
#3	2	+	Not detected	A1 (6276)				A2 (3143), A36, Dp18, Dp28, Dr4, Dr7 (5146), Dr9
#4	2	+	A3 (9481), A24 (8733), B7 (5145), B35 (7811)	A1 (7811), A2 (13 530), B57 (13 676)	NA	NA	NA	A11 (5559), A23 (5700), A36 (5754), A68 (7109), A69 (8173), A80(4145), B42 (4319), B46 (5541), B51 (7940), B53 (7624), B55 (3776), B56 (4343), B58 (10 903), B67 (4248), B71 (3667), B75 (5007), B77 (3982), B78 (5101), B81 (3521) Dp28, Dq7 (16 095), DqA1 (20 321)Dq8 (14 533), Dq9 (12 547), Dr16
#5	3	-	Not detected	Not detected	Not detected	NA	NA	Not detected
#6	4	+	A24 (14 008), B47 (5594), B51 (16 956)	B51 (16 956), B81 (5771), DR1 (1293), DR7 (2359)	B53 (12 877), B63 (>3000), DR1 (1293)	A24 (14 008), DR1 (1293)	NA	A23, A25, A32, A66, B13, B27, B35, B37, B38, B42, B44, B45, B49, B52, B55, B56, B57, B58, B59, B60, B61, B67, B7, B73, B76, B77, B78, B82, Cw17, Cw2, Dq4, Dr11, Dr13, Dr4, Dr51

Continuation - Table S1.

#7	5	+	A3 (8159), B18 (3155), B50 (15 884)	A74 (6054)	A24 (9114), A32 (15 083), B18 (3155), B52 (10 739)	A3 (8159), B44 (9256), B63 (15 161)	A74 (6054)	B49 (19 759), B72 (16 873), B53 (11 988), B62 (16 228), B71 (12 160), B51 (13 304), B57 (13 961), B38 (11 821), A23 (11 269), B77 (12 847), B59 (10 836), B35 (7904), B58 (12 389), A25 (11 162), B75 (8189), B13 (7735), B56 (12 825), B27 (6003), B37 (5588), B45 (8258), B78 (4963), B47 (5906), B41 (4864), B60 (3824), B61 (3713), B76 (5892), B46 (5434), Dr7, Dr4, Dr13, Dq6, Dr103, Dr16, Dq9, Dq8, Dr12, Dr11, Dr51, Dr9, Dr8, Dr53
#8	1	-	Not detected	NA	NA	NA	NA	Not detected
#9	1	-	Not detected	NA	NA	NA	NA	DQA1 (5973)
#10	3	-	Not detected	Not detected	Not detected	NA	NA	A1, A36
#11	1	+	B7 (6782)	NA	NA	NA	NA	Dr7 (5269), B81 (6471), B48 (5461), B60 (4287)
#12	1	-	Not detected	NA	NA	NA	NA	Not detected
#13	1	-	Not detected	NA	NA	NA	NA	A1, A36

Abbreviations: IA, Islet Transplant Alone; MFI, mean fluorescence intensity; NA, nonapplicable.

Table S2 – Values of cPRA (%) in ITx+BM group subjects before transplantation, during transplant follow-up, and after graft failure.

Subject	cPRA (%) Pretransplant	cPRA (%) 1/2 GS	cPRA (%) Graft failure	cPRA (%) 7 y post-GF	cPRA (%) 8 y post-GF	cPRA (%) 9 y post-GF	cPRA (%) 10 y post-GF
#1	0	0	0	100	100	100	98
#2	0	0	0	n/a	99	93	90
#3	n/a	97	97	n/a	97	100	100
#4	n/a	n/a	0	n/a	n/a	51	0
Subject	cPRA (%) 11 y post-GF	cPRA (%) 12 y post-GF	cPRA (%) 13 y post-GF	cPRA (%) 14 y post-GF	cPRA (%) 15 y post-GF	cPRA (%) 16 y post-GF	cPRA (%) 17 y post-GF
#1	95	99	99	100	98	Enrolled ^a	Enrolled ^a
#2	83	95	93	85	88	Enrolled ^a	Enrolled ^a
#3	100	96	97	97	97	97	Enrolled ^a
#4	0	0	0	0	0	0	41

Abbreviations: 1/2 GS, half-life graft survival; cPRA, calculated panel-reactive antibody; GF, graft failure; ITx+BM, islet transplantation plus bone marrow-derived CD34+ hematopoietic stem cells; n/a, data not available; PRA, panel-reactive antibody.

^aEnrolled: patients have not reached this evaluation point (still enrolled in the protocol).